- Non-invasive prenatal testing (NIPT)
- Pre-implantation genetic screening (PGS)
- Pre-implantation genetic diagnosis (PGD)
- BRCA 1 & 2 panel
- Cancer hotspot panel
- Lung Cancer mutation panel
- RAS Extended Plus for Colorectal Cancer
- Thyroid cancer mutation profile
- AML mutation panel
- GIST mutation panel
- Prostate cancer mutation panel
- ABL1 TKI resistance mutations
- MPN mutations
- TP53 mutation
- GIST mutation panel
- IDH1 & IDH2 mutations for glioma
- KIT D816V mutation
- FGFR3 mutation for bladder cancer
- BCR-ABL detection
- PML-RARA detection
- ALL translocation panel
- AML translocation panel
- HLA typing
- Paternity testing
BRCA 1 & 2 panel
BRCA 1 & 2 panel
BRCA1 and BRCA2 are two related genes, the changes (mutations) of which have been known to increase the risk of breast, ovarian & prostate cancers. In general, about 69-72% of women who inherit a harmful BRCA1 or BRCA2 mutation will develop breast cancer, and 17-44% of women who inherit these mutations will develop ovarian cancer by the age of 80. BRCA2 mutations are also the most common genetic factor in prostate cancers. Since these mutated genes are inherited from parents, identifying the presence of these mutations in healthy family members can help in early diagnosis of breast, ovarian or prostate cancers or prevention of these cancers altogether.